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ABSTRACT
Background. Prospective database studies can provide useful information regarding ‘real-world’ outcomes and drug efficacy.
Objective. To determine the early predictors of suboptimal treatment responses at two and three years under injectable Dis-
ease Modifying Therapy (DMT). 
Methods. This was a multi-centre prospective database study. Adult patients who started injectable DMTs between January 
2008 and June 2013 were included. The follow-up continued until July 2014. Suboptimal treatment responses were defined as: 
the presence of clinical relapse and/or Expanded Disability Status Score (EDSS) progression and/or newly emerging T2 lesions 
or/and gadolinium enhancing lesions on magnetic resonance imaging (MRI). The parameters were assessed up to 24 months 
prior to, and every 12 months during, the treatment.
Results. Analysis included 297 MS (multiple sclerosis) patients followed for a mean time of 2.3 ± 1.3 years (range 1–5). Within 
the three years of observation, the persistence and efficacy with injectable DMTs was high. With increased disability, defined 
by EDSS ≥ 3, the risk of treatment failure increased up to seven times, OR 7.33 in the second year radiological analysis (CI 95% 
: 1.69–29.2) p < 0.01, similar to over two times in the second year clinical analysis, with the baseline symptomatic hemiparesis 
OR 2.75 (CI 95% : 1.06–7.06) p 0.034. A high relapse rate one year prior to treatment adversely influenced the treatment success 
at three years, OR 3.04 (CI 95% : 1.49–8.43) p < 0.01.
Conclusions . Injectable DMTs should not be chosen for treatment initiation in motoric disabled patients (EDSS ≥ 3) with a high 
grade of clinical activity. These drugs are effective in less active relapsing-remitting (RR) MS patients.
Key words: multiple sclerosis, disease modifying treatment, annualised relapse rate, Expanded Disability Status Score, mag-
netic resonance imaging, RIO score, efficacy 
(Neurol Neurochir Pol 2019; 53 (2): 131–137)
Introduction
Multiple sclerosis (MS) is a chronic demyelinating dis-
ease with increasing prevalence in Poland [1]. The course of 
the disease and its associated rate of disability progression 
are highly unpredictable and constitute the most common 
primary neurological cause of disability in young adults 
[2]. The continued development of diagnostic criteria 
and increased awareness of typical clinical features have 
allowed shortening of the diagnosis delay and an earlier 
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initiation of treatment [3]. An analysis of the disease onset 
symptoms and initial relapse rate can help to estimate the 
most probable course of the disease, with specification as 
to its aggressiveness [4]. However, the question as to which 
drug should be chosen for the treatment is still unresolved. 
The country-wide standardised inclusion and reassessment 
criteria allowed us to make joint analyses of patients from 
different centres at a time when only injectable disease 
modifying treatments (DMT) were available in Poland. First 
line injectable treatment options included different formu-
lations of interferon beta (INT-β): subcutaneous IFN-β-1b, 
IFN-β-1a and intramuscular IFN-β-1a or subcutaneous 
glatiramer acetate (GA). These are well established safety 
immunomodulatory drugs with all-over efficacy defined 
in randomised trials at about 30% [5–8]. This includes 
a moderate influence on lowering the relapse rate and on the 
clinical and radiological progression of disability. At a time 
when there are a growing number of newly available treat-
ment options, it is still important to analyse previously used 
algorithms, either to reestablish them or to ensure correct 
treatment decisions [9]. 
Material and methods 
Patients
The research design was a multi-centre prospective 
database study. Four medical centres (Bydgoszcz, Szczecin, 
Białystok, Zabrze) providing immunomodulatory treatment 
of MS within the nationally funded treatment programme 
participated in the research. 
Inclusion criteria: adult (over 18 years old) patients with 
relapsing-remitting (RR) MS who started an injectable DMT 
between January 2008 and June 2013 were included in this 
study. The follow-up continued to July 2014. All participants 
met the 2005 McDonald criteria for MS and had either two 
relapses or one relapse and a chronologically (three months) 
separate gadolinium enhancing lesion on magnetic reso-
nance imaging (MRI), within the immediate two year period 
preceding the start of DMT [3]. We included either patients 
with a newly confirmed diagnosis or untreated for at least the 
last six months with a new exacerbation and an Expanded 
Disability Status Score (EDSS) of up to 4.5. During the time 
of data collection (between 2008 and 2011), the treatment 
duration regime in Poland was limited to three years. Some 
active patients could be recruited several times, always after 
a new instance of disease exacerbation. Treatment selection 
for IFN β or GA was based on national eligibility criteria. 
Patients with Clinical Isolated Syndrome (CIS) or progressive 
forms of MS were not eligible for this study. 
Ethics
The work described in this article has been carried out 
in accordance with The Code of Ethics of the World Medical 
Association (Declaration of Helsinki) for experiments in-
volving humans; we have followed uniform requirements for 
manuscripts submitted to biomedical journals. 
Cohorts
The time of treatment initiation and a follow-up period 
of a minimum of two years allowed us to make a comparative 
observation of two cohorts. Cohort A comprised patients 
included from January 2008 up to May 2012, eligible after at 
least two relapses during the last 24 months before qualifica-
tion to the treatment. Cohort B comprised patients included 
from June 2012, eligible after at least one relapse during the 
last 12 months before qualification to the treatment.
Method
Patient data was collected in an electronic case report 
form. Clinical and demographic parameters were analysed. 
The disease activity was determined by the annualised relapse 
rate (ARR) defined as: MS-related hospitalisation, MS-related 
Emergency Room visit or MS-related outpatient visit with 
corticosteroid prescription ± 7 days within one year. EDSS 
scoring was performed every three months during the treat-
ment by trained staff [10]. Clinical neurological progression 
was defined as a change of EDSS score of more than 1.0 that 
was persistent for longer than three months despite a lack of 
relapse. Magnetic resonance imaging (MRI) was performed 
at the beginning and after each year of treatment, and was 
focused on detecting new emerging T2 lesions or/and a gado-
linium (GD) enhancing lesion.
Outcomes were defined on the basis of the RIO score:
Optimal clinical response is described as no relapses, 
no progression in disability (defined as stable EDSS or with 
a change of less than 1.0) within a year. Optimal radiological 
response is defined as no changes in NMR (no gadolinium 
enhancing lesion and less than two T2 lesions). The definition 
is similar to a RIO score of zero. Suboptimal clinical response 
is described as one or more relapse and/or progression in dis-
ability (defined as increase of EDSS ≥ 1.0) and/or suboptimal 
radiological response, defined as > 1 active gadolinium en-
hancing lesion and/or > 2 T2 lesions in a year. This definition 
is similar to a RIO score of 1 or more [11].
Statistics 
Statistical analysis was performed using R (The R Project 
for Statistical Computing)-R version 3.4.2. In descriptive 
statistics, the following tests were used: Fisher’s exact test to 
establish differences in proportions, T-test to establish dif-
ferences in quantitative data (for normally distributed data), 
Wilcoxon test to establish differences in quantitative data (for 
non-normally distributed data), Anderson-Darling test to 
establish the normality of given quantitative data. In order to 
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determine the influence of main neurological rates (symptoms 
on MS onset, EDSS) on drugs suboptimal response, univari-
able logistic regressions were performed.
Results
Two hundred and ninety seven MS patients met the inclu-
sion criteria. The female to male ratio was 2.3:1. The average 
age of the patients was 35.37 ± 9.92 years (range 18–64 years), 
and the patients showed mild disability characterised by 
a mean baseline EDSS of 1.95 ± 1.05. The average treatment 
delay was 4.12 ± 4.81 years (range 0–24 years). The two studied 
cohorts were comparable without significant differences on 
baseline, except for the fact that the more recently included 
patients (Cohort B) were older, more disabled and more 
active in their disease course (p 0.01). In both cohorts, the 
proportion between the newly diagnosed-naïve and previ-
ously treated patients was similar (Tab. 1).
Clinical outcome with injectable DMT
Over 85% of patients were under INF β treatment with 
a mean follow-up time of 2.3 ± 1.3 years (range 1–5). After 
three years of treatment, no relapses and stable EDSS was 
observed in 91 patients (85%) which constitutes about one 
third of the baseline population. The patient loss in follow-up 
was mainly due to a treatment time limited to three years, 
established by the nationally funded treatment programme. 
The evidence of suboptimal treatment response defined as 
evidence of clinical and/or radiological activity, was stable in 
the follow up-period, within the range of 15–18%. The reason 
for stopping or switching the initial DMT therapy was mainly 
driven by the instability of the clinical course. The mean EDSS 
score was stable over three years of treatment at about 2.0; we 
also observed a significant and stable reduction of ARR and 
GD enhancement p < 0.01 (Tab. 2).
Main predictors of suboptimal response to 
injectable DMT in three years follow-up
Suboptimal clinical response, defined as a RIO score ≥ 1, 
was further analysed in two separate categories: clinical and 
radiological response. In univariable logistic regression, the 
factors predicting worse response to injectable DMTs were 
comparable in the whole three years of the follow-up period. 
The main predictor of inefficacy in the first and second years 
of treatment was the baseline clinical status. With an increase 
in disability defined as baseline EDSS ≥ 3, the risk of treat-
ment failure increased to over seven times (in the second year 
radiological analysis), similar to over two times with baseline 
symptomatic hemiparesis, which in fact influences the EDSS 
Table 1. Socio-demographic and clinical characteristics of MS patients at baseline
Variable Overall 
(297)
Cohort A  
(n = 150)
Cohort B  
(n = 147)
p value
Age (years) mean (SD) 35.37 (9.92) 33.86 (9.42) 36.92 (10.2) 0.01**
Gender (female/male), n 206/91 100/50 106/41 0.38
Age at diagnosis (years) mean (SD) 31.26 (10.12) 29.94 (9.38) 32.60 (10.69) 0.06
Treatment delay (years) mean (SD) range 4.12 (4.81)
(0–24)
3.92 (4.64)
(0–23)
4.32 (4.98)
(0–24)
0.8
Previous DMT treatment (No/Yes), n 212/85 107/43 105/42 1.0
BL treatment INF/GA, n 253/44 133/17 120/27 0.1
Onset symptoms: n/%
Optic neuritis: n/% 99/33.4 52/33.8 47/31.5 0.71
Hemiparesis: n/% 77/25.9 42/28.0 35/24.2 0.43
Cerebellar syndrome: n/% 35/11.8 19/12.6 17/11.6 1.0
Brainstem syndrome: n/% 31/10.4 16/10.6 15/10.2 1.0
Other: n/% 55/18.5 21/14.0 33/22.5 0.2
EDSS on BL mean (SD) 1.95 (1.05) 1.75 (0.97) 2.15 (1.10) 0.01*
EDSS ≥ 3 on BL n/% 44/14.81 16/10.66 28/19.04 0.05*
NMR GD enhancement on BL 62/297 18/132 44/103 < 0.01**
ARR 2 years before BL (SD) 1.535 (0.95) 1.37 (0.86) 1.70 (0.96) 0.01*
ARR 1 year before BL (SD) 1.18 (0.78) 1.0 (0.68) 1.36 (0.89) 0.01*
ARR 6 months before BL (SD) 0.89 (0.68) 0.71 (0.56) 1.07 (0.81) 0.01*
p value represents the statistical difference between the two cohorts; *Wilcoxon test ; **Fisher test; ARR — annual relapse rate; BL — baseline; DMT — disease modifying therapy; EDSS — Expanded Disability 
Status Score; MRI — magnetic resonance imaging; SD — standard deviation
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Table 2. Clinical characteristics of MS patients during treatment
Variable BL I year II year III year p value
Overall patients, n 297 297 167 107 -
EDSS mean (SD) 1.95 (1.05) 1.96 (1.12) 1.96 (1.12) 2.018 0.84
ARR (SD) 1.53 (0.95) 0.13 (0.41) 0.13 (0.41) 0.13 (0.41) < 0.01
NMR GD enhancement mean (SD) 0.54 (1.42) 0.06 (0.32) 0.06 (0.32) 0.06 (0.32) < 0.01
Continued treatment n/% - 283/95.0 161/96.4 104/97.2 0.43
Optimal clinical/radiological response 
(RIO 0) n/%
- 244/82.2 142/85.0 91/85.0 0.52
Suboptimal clinical/radiological response (RIO ≥ 1) n/% - 53/17.8 25/15.0 16/15.0 0.51
p value represents the statistical difference between the analysed groups; ARR — Annual Relapse Rate; BL — baseline; EDSS — Expanded Disability Status Score; GD — gadolinium; SD — standard deviation
Table 3. Main predictors of suboptimal response to injectable DMT in three years follow-up: univariable logistic regression
Suboptimal response Variable OR CI 95% p-value
First year clinical EDSS on BL 1.38 1.00–1.891 0.048
Hemiparesis on BL 2.17 1.04–4.406 0.034
First year radiological EDSS on BL 0.55 0.311–0.904 0.026
Age at treatment initiation 0.93 0.88–0.98 0.02
Second year clinical Hemiparesis on BL 2.75 1.065–7.066 0.034
Second year radiological EDSS on BL 2.13 1.143–4.072 0.018
EDSS on BL ≥ 3 7.33 1.69–29.206 < 0.01
Third year clinical ARR one year prior to treatment 3.047 1.322–7.71 0.01
Third year radiological ARR one year prior to treatment 3.667 1.325–12.636 0.029
ARR — Annual Relapse Rate; BL — baseline; EDSS — Expanded Disability Status Score
score. The younger age and lower EDSS on treatment initia-
tion positively influenced optimal radiological response in 
the first year. With longer treatment duration, the ARR one 
year before the treatment initiation seems to play a negative 
role. With a higher relapse rate, the suboptimal response risk 
increased three times in the third year of treatment. No other 
demographic or clinical factors played a role in predicting 
a worse outcome (Tab. 3).
Discussion
Open compartmental studies concerning first-line RRMS 
treatment have shown a significant reduction of disease acti-
vity. In the first two years of INF B treatment, the ongoing 
disease activity has been reported as between 16% and 29% 
[12–16]. Freedom from disease activity has become a wi-
dely proposed system of optimal clinical outcomes analysis 
based on relapse rate, EDSS and radiological signs of new 
active lesions. The often used RIO score can be translated to 
NEDA showing an optimal disease control in a similar way 
[16–18]. In this multi-centre prospective database study, we 
showed a high efficacy of injectable first-line DMTs. This was 
achieved by a good clinical response in lowering the BL rate 
of ARR from 1.3 to 0.13 (after one and two and three years of 
treatment). EDSS stabilization, together with the reduction 
of radiological progression, resulted in good disease control 
in over 80% of patients.
Some other studies, in so far as our results, show high 
efficacy of first-line injectable medications in the treatment 
of RRMS patients [18–23]. In the study by Sorenson et al., 
based on the Danish Nationwide Database containing health 
records from RRMS patients, there was no clear difference in 
the efficacy of immunomodulatory treatment with injectable 
DMTs [22, 24–25].
We based the comparison of the optimal and suboptimal 
treatment responses on the RIO score. To analyse the pre-
dictors for suboptimal response, we concentrated mainly on 
baseline variables that could lead to treatment failure. Baseline 
EDSS ≥ 3 or hemiparesis as the initial MS manifestation incre-
ases such a risk more than two times. A similar conclusion 
without any specific cut-off was described in an 18 year-long 
observational cohort study of treatment-naïve patients from 
Canada [19]. Also in other reports, high EDSS score has been 
considered to be the main factor predicting interruption of 
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therapy, which in fact is similar to a suboptimal treatment 
response [26–27]. Due to the therapy outcome optimisation, it 
is recommended attention be paid to more active/progressive 
patients at diagnosis [4]. Those patients with higher levels of 
disability in the early relapsing-remitting course of the disease 
should be considered as highly active, with an indication for 
therapeutic decisions other than first line DMTs [9]. The 
same is true for relapse active patients before the treatment, 
as relapses are the clinical manifestation of inflammation. In 
our cohort, the risk of being suboptimal responders at three 
years was more than three times higher for relapse active 
patients one year before treatment.
Another important aspect that we took into consideration 
was treatment efficacy estimation by early and late therapy 
initiation. We could compare the outcomes form treatment-
-naive and retreated patients. This observation was possible 
because of country-specific regulation on the time of data 
collection. According to the previously used (from 2008 to 
2012) guidance, the nationally funded treatment programme 
was limited to three years. Some active patients could be 
recruited several times, always after a new exacerbation of 
the disease. The average treatment delay in our study was 
four years. Only 28% (85) of patients were treated within 
> 12 months after diagnosis as treatment-naïve. Nearly 27% 
started the treatment later than five years, and 11% later than 
10 years, after diagnosis. Despite not proven worsening of 
efficacy, treatment delay in our study was twice as long as that 
observed in a comparable time frame in Spain [28]. Taking 
into consideration the differences between treatment-naïve 
and retreated patients, we could only confirm a worse outco-
me in patients with profound clinical disability on treatment 
initiation, without differences between these two groups.
In previous Polish analysis, immunomodulatory drugs 
were used in only 24% of patients: mainly INF β (81%) and 
GA (13%) [29]. This time, the analysis showed a similar 
proportion and consistent INF β dominance, in contrast to 
other countries [19]. In a similar observation period in the 
US, nearly 40% of newly-diagnosed MS patients were on 
treatment [30]. This shows that the problem with treatment 
initiation is not only related to country-specific regulations 
or budget, but also to patients’ and physicians’ beliefs in its 
efficacy and safety. 
In a long term observation of injectable DMTs, the stop/
switch rates were mainly dependent on treatment duration, 
with intolerance as the primary reason for stopping, follo-
wed by inefficacy [19, 31–37]. Persistence in specific therapy 
indirectly describes the treatment efficacy. In our study, the 
efficacy was over 80% but the persistence was influenced 
rather by no other treatment options at that time. 
Our study had some methodological shortcomings due 
to its multi-centre nature. Follow-up MRI scans were per-
formed and analysed in different locations, albeit under one 
assessment protocol [38]. The same is true for EDSS scoring. 
An average treatment delay estimated as almost four years 
after MS diagnosis is another limitation of our study. Howe-
ver, this reflected the fact that country-specific qualification 
procedures led to late initiation of the treatment, which is 
inconsistent with common standards. We could determine 
the baseline predictive correlations only in univariate logistic 
regression analysis. 
Many novel MS medications have been registered recently 
[39] and integrated to an improved MS treatment program-
me in Poland. Confronting the previously used algorithms 
with well-established outcomes control (RIO score) that we 
have used so far provides the insight that injectable DMTs 
are effective in RRMS patients (causing lowering of ARR 
and disease activity reflected in MRI) with limitation to less 
active and less clinically well patients. Our findings confirm 
that a careful baseline variables assessment can be helpful in 
predicting treatment response in injectable first-line drugs.
Conclusions
Patients with greater disability (EDSS ≥ 3) at treatment 
initiation or hemiparesis as the initial symptom were more 
likely to fail at the second year of treatment. A high relapse 
rate one year prior to treatment adversely influences the 
treatment success at three years. Our findings confirm that 
first-line injectable drugs should not be chosen for treatment 
initiation in motoric disabled patients with a high grade of 
clinical activity. These drugs are effective in less active MS-
-RR patients.
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